These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 3491344)
1. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. McGeer PL; Kamo H; Harrop R; McGeer EG; Martin WR; Pate BD; Li DK Neurology; 1986 Dec; 36(12):1569-74. PubMed ID: 3491344 [TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. Alavi A; Newberg AB; Souder E; Berlin JA J Nucl Med; 1993 Oct; 34(10):1681-7. PubMed ID: 8410281 [TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063 [TBL] [Abstract][Full Text] [Related]
4. Positron emission tomography imaging of regional cerebral glucose metabolism. Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938 [TBL] [Abstract][Full Text] [Related]
5. [Comparison study of positron emission tomography, X-ray CT and MRI in parkinsonism with dementia]. Okada J; Peppard R; Calne DB Nihon Igaku Hoshasen Gakkai Zasshi; 1989 May; 49(5):643-56. PubMed ID: 2798056 [TBL] [Abstract][Full Text] [Related]
7. Comparison of CT, MR, and PET in Alzheimer's dementia and normal aging. Fazekas F; Alavi A; Chawluk JB; Zimmerman RA; Hackney D; Bilaniuk L; Rosen M; Alves WM; Hurtig HI; Jamieson DG J Nucl Med; 1989 Oct; 30(10):1607-15. PubMed ID: 2795200 [TBL] [Abstract][Full Text] [Related]
8. PET of brain amyloid and tau in mild cognitive impairment. Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990 [TBL] [Abstract][Full Text] [Related]
9. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. Piert M; Koeppe RA; Giordani B; Berent S; Kuhl DE J Nucl Med; 1996 Feb; 37(2):201-8. PubMed ID: 8667045 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126 [TBL] [Abstract][Full Text] [Related]
11. Multimodal Discrimination of Alzheimer's Disease Based on Regional Cortical Atrophy and Hypometabolism. Yun HJ; Kwak K; Lee JM; PLoS One; 2015; 10(6):e0129250. PubMed ID: 26061669 [TBL] [Abstract][Full Text] [Related]
12. In vivo imaging of region and cell type specific neocortical neurodegeneration in Alzheimer's disease. Perspectives of MRI derived corpus callosum measurement for mapping disease progression and effects of therapy. Evidence from studies with MRI, EEG and PET. Hampel H; Teipel SJ; Alexander GE; Pogarell O; Rapoport SI; Möller HJ J Neural Transm (Vienna); 2002 May; 109(5-6):837-55. PubMed ID: 12111472 [TBL] [Abstract][Full Text] [Related]
13. Cerebral Hypoperfusion and Hypometabolism Detected by Arterial Spin Labeling MRI and FDG-PET in Early-Onset Alzheimer's Disease. Verclytte S; Lopes R; Lenfant P; Rollin A; Semah F; Leclerc X; Pasquier F; Delmaire C J Neuroimaging; 2016; 26(2):207-12. PubMed ID: 26031943 [TBL] [Abstract][Full Text] [Related]
14. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Tosun D; Schuff N; Jagust W; Weiner MW; Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336 [TBL] [Abstract][Full Text] [Related]
15. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. Ota K; Oishi N; Ito K; Fukuyama H; ; J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777 [TBL] [Abstract][Full Text] [Related]
16. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432 [TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in Alzheimer's disease. Duara R; Grady C; Haxby J; Sundaram M; Cutler NR; Heston L; Moore A; Schlageter N; Larson S; Rapoport SI Neurology; 1986 Jul; 36(7):879-87. PubMed ID: 3487046 [TBL] [Abstract][Full Text] [Related]
18. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Engler H; Lundberg PO; Ekbom K; Nennesmo I; Nilsson A; Bergström M; Tsukada H; Hartvig P; Långström B Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):85-95. PubMed ID: 12483414 [TBL] [Abstract][Full Text] [Related]
19. PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. Groom GN; Junck L; Foster NL; Frey KA; Kuhl DE J Nucl Med; 1995 Dec; 36(12):2207-10. PubMed ID: 8523106 [TBL] [Abstract][Full Text] [Related]
20. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Higuchi M; Tashiro M; Arai H; Okamura N; Hara S; Higuchi S; Itoh M; Shin RW; Trojanowski JQ; Sasaki H Exp Neurol; 2000 Apr; 162(2):247-56. PubMed ID: 10739631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]